Neurology and psychiatry are challenging areas for medical diagnosis and treatment. Psychiatric and neurological disorders are the subject of rapid scientific developments particularly regarding the role of centrally-active treatments.

Solvay psychiatric research has contributed substantially to the current knowledge of the role of serotonin in a wide variety of psychiatric disorders. The Solvay anti-depressant fluvoxamine was the first SSRI to reach the market (in 1983).

Another area of Solvay psychiatric research is bifeprunox which presents various benefits in long term maintenance for schizophrenia patients.

Parkinsons’s disease medication, DUODOPA® is Solvay’s first commercial contribution to patients suffering from the late stage of the malady.